IMT-2021-0002_supplementaryfigure2.docx (85.37 kB)

IMT-2021-0002_supplementaryfigure2.docxSupplementary Material - Pretreatment Lung Immune Prognostic Index as biomarker in NSCLC cancer patients receiving first line pembrolizumabSupplementary Material - Pretreatment Lung Immune Prognostic Index as biomarker in NSCLC cancer patients receiving first line pembrolizumab

figure

posted on 2021-06-30, 14:17 authored by Figshare Future Science GroupFigshare Future Science Group, Veccia Antonello, Sforza Vincenzo, Vattemi Emanuela, Inno Alessandro, Kinspergher Stefania, Dipasquale Mariachiara, Gori Stefania, Morabito Alessandro, Baldi Ileana, Caffo Orazio

Supplementary Figure 2. PFS according to LIPI groups.

Abstract

Aims

Investigate the role of pretreatment Lung Immune Prognostic Index (LIPI) as biomarker in PDL1≥50% NSCLC patients receiving pembrolizumab.

Patients and methods

We retrospectively identified 117 patients, divided into 3 prognostic groups according to LIPI score. For each patient we evaluated 1-year overall survival (OS) and progression free survival (PFS) rate. C-statistic and survival ROC curves were used to study discrimination of LIPI.

Results

After a median follow-up of 11.7 months, 1-year OS rate was 60.1%, 35.3% and 28.6%, while 1-year PFS rate was 39.1%, 20.6% and 14.3% in good, intermediate and poor LIPI groups, respectively (p<0.001). The c-statistic and AUC of LIPI were 0.63 and 0.662 for OS and 1-year OS, respectively.

Conclusions

Higher LIPI score is related to worse survival in advanced NSCLC patients treated with first-line pembrolizumab. However, based on c-statistic and AUC, LIPI does not represent a good prognostic survival model.